论文部分内容阅读
目的研究血必净联合甲基强的松龙在急性支气管哮喘(bronchial asthma)临床对比观察应用价值。方法采用回顾性研究,收集新疆部分地区2010年1月至2012年1月支气管哮喘急性发作145例,随机分为研究组和对照组,分别采用血必净联合甲基强的松龙治疗和常规甲基强的松龙治疗,比较两组临床。结果两组患者支气管哮喘急性发作的临床表现和实验室检查结果出现差异,研究组和对照组有效率分别为96%和72%,经χ2后,差异学有统计学意义(χ2=8.42,P<0.05),研究组的疗效优于对照组。结论血必净联合甲基强的松龙治疗支气管哮喘急性发作期临床类疗效,优于单用甲基强敌松龙。值得临床推广。
Objective To study the clinical value of Xuebijing combined with methylprednisolone in acute bronchial asthma. Methods A retrospective study was conducted to collect 145 acute exacerbations of bronchial asthma in some areas of Xinjiang from January 2010 to January 2012. The patients were randomly divided into study group and control group, treated with Xuebijing combined with methylprednisolone and conventional Methylprednisolone treatment, comparing two groups of clinical. Results The clinical manifestations and laboratory findings of acute exacerbation of bronchial asthma in the two groups were different. The effective rates of the study group and the control group were 96% and 72%, respectively. After 2 years, the difference was statistically significant (χ2 = 8.42, P <0.05), the study group is better than the control group. Conclusion Xuebijing combined with methylprednisolone treatment of acute bronchial asthma clinical efficacy, superior to methyl prednisolone alone. Worth clinical promotion.